WPRIM Management System> DCMS> Journal of Clinical Hepatology> 2023> 39> 1

Volume: 39 Issue: 1

1. Expanding the treatment of chronic hepatitis B Page:10—13
2. Hemodynamic characteristics of proper hepatic artery and portal vein in patients after splenectomy and devascularization Page:104—109
3. Establishment and validation of a nomogram risk prediction model for infection complications in patients after hepatectomy for liver cancer Page:110—117
4. Predictive value of preoperative alkaline phosphatase to prealbumin ratio in prognosis and postoperative complications in patients with hepatocellular carcinoma after radical tumor resection Page:118—127
5. Expression of peripheral CD100 and its regulation to T lymphocytes function in patients with hepatocellular carcinoma Page:128—136
6. ｜Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials Page:136—136
7. Association of energy metabolism with serum thyroid hormone levels in patients with liver failure and their impact on prognosis Page:137—141
8. Thoughts on expert opinion on expanding antiviral therapy for chronic hepatitis B Page:14—21
9. Focal nodular hyperplasia-like nodules in liver cirrhosis: An imaging analysis of three cases Page:142—146
10. A case of chronic gelatinous ascites caused by giant intraductal papillary mucinous neoplasm of the bile tract Page:147—151
11. ｜ Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B Page:151—151
12. Primary mucoepidermoid carcinoma of the liver: A case report and literature review Page:152—155
13. Research advances in tenofovir alafenamide fumarate in treatment of special chronic hepatitis B Page:156—161
14. Role of glucose and lipid metabolism mediated by the bile acid receptor Takeda G protein-coupled receptor 5 in nonalcoholic fatty liver disease Page:162—167
15. Mechanism of lipid metabolism mediated by hepatokines and adipokines in nonalcoholic fatty liver disease Page:168—174
16. Role of pyroptosis in nonalcoholic fatty liver disease Page:175—180
17. Role of organelle interaction in the development and progression of nonalcoholic fatty liver disease Page:181—187
18. Treatment of primary biliary cholangitis by targeting intestinal flora Page:188—191
19. Research advances in the reversal of liver fibrosis Page:193—198
20. Advances in direct oral anticoagulants in the treatment of cirrhosis-associated portal vein thrombosis Page:199—203
21. Research advances in systemic inflammatory response of acute decompensated cirrhosis patients Page:205—210
22. ｜Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma Page:21—21
23. Application and potential value of endogenous lipid mediators in liver failure Page:211—217
24. Immune escape of hepatic echinococcosis based on the PD-1/PD-L1 signaling pathway Page:218—225
25. Expanding the indications for antiviral therapy for chronic hepatitis B: Advantages and disadvantages Page:22—26
26. Research advances in the impact of phthalates on cholestatic liver disease Page:226—230
27. Research advances in the risk factors for recurrence of common bile duct stone after choledocholithotomy Page:231—237
28. Expanding initial anti-HBV therapy for chronic hepatitis B: Reducing the treatment threshold of alanine aminotransferase Page:27—30
29. Early initiation of antiviral therapy reduces the risk of hepatocellular carcinoma in individuals with chronic hepatitis B virus infection Page:31—36
30. Do HBV DNA-negative HBsAg-positive patients with compensated hepatitis B cirrhosis need antiviral therapy? Page:37—42
31. Highlights of the EASL clinical practice guidelines on sclerosing cholangitis versus the latest Chinese guideline Page:43—49
32. Serum levels of soluble programmed death-1 and soluble programmed death-ligand 1 in chronic hepatitis B patients with clinical cure and their clinical features Page:50—55
33. Expression levels of HBV pregenomic RNA and hepatitis B core-related antigen in circulating serum and their association with recurrence in chronic hepatitis B patients after withdrawal from nucleos(t)ide analogues Page:56—62
34. Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis Page:63—69
35. Clinical characteristics and prognosis of acute on chronic liver failure in patients with recompensatory hepatitis B cirrhosis Page:70—76
36. Expression and significance of immune cells in patients with hepatitis B virus-related acute-on-chronic pre-liver failure Page:77—82
37. Current reviewers Page:82—82
38. Association between serum alkaline phosphatase and type 2 diabetes mellitus with nonalcoholic fatty liver disease Page:83—88
39. Role of glutathione transferase in nonalcoholic fatty liver disease: An analysis based on gene expression profile Page:89—96
40. Fly in the Wind, Take a Lead—Speech of the Editors-in-Chief of Page:9—9
41. Diagnostic value of real-time shear wave elastography for liver fibrosis in patients with autoimmune hepatitis Page:97—103

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.